Achromobacter xylosoxidans totally implantable venous access device infection in a person with cystic fibrosis: Complex management considerations
Ieuan E. S. Evans, Haris Haqqani, Daniel Smith, David W. Reid · 2024
Read Achromobacter xylosoxidans totally implantable venous access device infection in a person with cystic fibrosis: Complex management considerations by Ieuan E. S. Evans, Haris Haqqani, Daniel Smith, David W. Reid (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11631499.txt.
Description
Ieuan Evans and co-authors report a hard-to-treat port infection in a person with cystic fibrosis in a 2024 case paper. Implanted venous ports give steady access for treatment, but they can become infected. Usual culprits are skin staphylococci. Here the germ was Achromobacter xylosoxidans, in what the authors call the first such case in cystic fibrosis.
The infection seeded the blood and grew an infected clot where the port's line met the heart. Removing the device and choosing antibiotics posed tangled choices, which the paper walks through. Long treatment ended in full recovery. The authors use the case to question whether ports still earn their risks. New modulator drugs have improved health in cystic fibrosis, shrinking the need for permanent access. They urge regular review of every retained port.
Catalog record
| CREATOR | Ieuan E. S. Evans, Haris Haqqani, Daniel Smith, David W. Reid |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |